|
|
News Breaks | | | | December 9, 2012 | | 12:35 EDT |  | CLDX | Final Celldex data on CDX-011 supports overall survival benefit
Celldex Therapeutics, announced final results from the company’s randomized Phase 2b EMERGE study of CDX-011 in patients with glycoprotein NMB (GPNMB)-expressing, advanced, heavily pretreated breast cancer. The results presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium confirm preliminary findings reported in May and establish proof of principle with evidence of higher activity in patient subgroups with high GPNMB expression, including those with triple negative disease. Thomas Davis, MD, Senior Vice President and Chief Medical Officer of Celldex Therapeutics, commented, “The mature results presented today confirm the preliminary results shown previously and support advanced clinical development of CDX-011, which may play a critical role in treating patients with advanced breast cancer. We look forward to discussions with the Food and Drug Administration later this month to design a pivotal study intended to support approval of CDX-011 for specific patients with breast cancer.” | |
|
News For CLDX From The Last 14 Days Check below for free stories on CLDX the last two weeks. |
|
|
| May 10, 2013 | | 07:24 EDT |  | CLDX | Credit Suisse to host a conference
 Subscribe for More Information | |
|
|
|
|
|
|
